Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

InMed and Mentari to merge by end of 2026

PUBLIC · INMSep 09, 2026•about 2 hours ago

Acquiring Company

InMed Pharmaceuticals

Acquired Company

Mentari Therapeutics

Vancouver

San FranciscoHealthcareBiotechnologyHealth CareTherapeutics

Description

InMed Pharmaceuticals Inc. has announced a proposed merger with Mentari Therapeutics, Inc. The combined entity is expected to operate under the Mentari name, focusing on migraine prevention therapies. The merger is anticipated to close in the fourth quarter of 2026, pending shareholder approvals and other conditions. Both companies are working on securing financing to enhance the merger's prospects.

Company Information

Company

InMed Pharmaceuticals

Location

815 W. HASTINGS STREET

Vancouver, British Columbia, Canada

About

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM

Don't miss InMed Pharmaceuticals's next move

Get an email the moment InMed Pharmaceuticals makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence

Strategic

ML-powered predictions for InMed Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Mentari Therapeutics?

Mentari Therapeutics was acquired by InMed Pharmaceuticals, based in Vancouver. The deal was reported on September 9, 2026. InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. InMed Pharmaceuticals is publicly traded (INM) and operates in Healthcare.

When did InMed Pharmaceuticals acquire Mentari Therapeutics?

InMed Pharmaceuticals's acquisition of Mentari Therapeutics was reported on September 9, 2026. InMed Pharmaceuticals Inc. has announced a proposed merger with Mentari Therapeutics, Inc. The combined entity is expected to operate under the Mentari name, focusing on migraine prevention therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Mentari Therapeutics do?

Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition. It is privately held, operating in Biotechnology, and is based in San Francisco.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

See plans Or book a demo